Molecular targeted therapy in melanoma: A way to reverse resistance to conventional drugs

Current Drug Delivery

Volumn 9, Issue 1, 2012, Pages 17-29

  Maira, Francesca ^a,c   Catania, Alessia ^a,c   Candido, Saverio ^a,c   Russo, Alessia Erika ^a,c   McCubrey, James A ^b,c   Libra, Massimo ^a,c   Malaponte, Grazia ^a,c   Fenga, Concettina ^b,c  

^a UNIVERSITY OF CATANIA   (Italy)

^b EAST CAROLINA UNIVERSITY   (United States)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Drug resistance; Melanoma; PI3K AKT mTOR; RAF MEK ERK; Sensitivity; Targeted therapy

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; FLUDARABINE; FOTEMUSTINE; HEAT SHOCK PROTEIN 90 INHIBITOR; INTERFERON; INTERLEUKIN 2; LOMUSTINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PACLITAXEL; PEGINTERFERON ALPHA2B; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAF PROTEIN; RAS PROTEIN; RECOMBINANT ALPHA2B INTERFERON; TAMOXIFEN; TEMOZOLOMIDE; UNINDEXED DRUG; VINBLASTINE; VINDESINE;

ABDOMINAL PAIN; ADOPTIVE IMMUNOTHERAPY; APOPTOSIS; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); COLON PERFORATION; DERMATITIS; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; ENDOPLASMIC RETICULUM STRESS; ENVIRONMENTAL FACTOR; FATIGUE; GENE MUTATION; HEPATITIS; HUMAN; HYPOPHYSITIS; HYPOTENSION; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; MELANOMA CELL; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VASCULAR LEAK SYNDROME; VOMITING; WHOLE BODY RADIATION;

EID: 83455218210     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720112798376032     Document Type: Review

References (97)

1. Russo, A.E.; Torrisi, E.; Bevelacqua, Y.; Perrotta, R.; Libra, M.; McCubrey, J.A.; Spandidos, D.A.; Stivala, F.; Malaponte, G. Melanoma: Molecular pathogenesis and emerging target therapies. Int. J. Oncol., 2009, 34(6), 1481-1489.
2. Ghosh, P.; Chin, L. "Genetics and genomics of melanoma" Expert. Rev. Dermatol., 2009, 4(2), 13.
3. Ko, J.M.; Velez, N.F.; Tsao, H. "Pathways to Melanoma" Semin. Cutan. Med. Surg., 2010, 29 (4), 210-217.
4. Leiter, U.; Meier, F.; Schittek, B.; Garbe, C. "The natural course of cutaneous melanoma" J. Surg. Oncol., 2004, 86(4), 172-178.
5. th ed.; Springer: New York, NY, 2010, pp 325-344.
6. Tarhini, A.A.; Agarwala, S.S.; Cutaneous melanoma: available therapy for metastatic disease. Dermatol. Ther., 2006, 19(1), 19-25.
7. Leo, F.; Cagini, L.; Rocmans, P.; Cappello, M.; Geel, A.N.; Maggi, G.; Goldstraw, P.; Pastorino, U. Lung metastases from melanoma: when is surgical treatment warranted? Br. J. Cancer, 2000, 83(5): 569-572.
8. Ollila, D.W.; Hsueh, E.C.; Stern, S.L.; Morton, D.L. Metastasectomy for recurrent stage IV melanoma. J. Surg. Oncol., 1999, 71(4), 209-213.
9. Gutman, H.; Hess, K.R.; Kokotsakis, J.A.; Ross, M.I.; Guinee, V.F.; Balch, C.M. Surgery for abdominal metastases of cutaneous melanoma. World J. Surg., 2001, 25(6), 750-758.
10. Fletcher, W.S.; Pommier, R.F.; Lum, S.; Wilmarth, T.J. Surgical treatment of metastatic melanoma. Am. J. Surg., 1998, 175(5), 413-417.
11. Herman, P.; Machado, M.A.; Montagnini, A.L.; D'Albuquerque, L.A.; Saad, W.A.; Machado, M.C. Selected patients with metastatic melanoma may benefit from liver resection. World J. Surg., 2007, 31(1), 171-174.
12. Rose, D.M.; Essner, R.; Hughes, T.M.; Tang, P.C.; Bilchik, A.; Wanek, L.A.; Thompson, J.F.; Morton, D.L. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch. Surg., 2001, 136(8), 950-955.
13. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J. Thorac. Cardiovasc. Surg., 1997, 113(1), 37-49. No author listed.
14. Rate, W.R.; Solin, L.J.; Turrisi, A.T. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int. J. Radiat. Oncol. Biol. Phys., 1988, 15(4), 859-864.
15. Herbert, S.H.; Solin, L.J.; Rate, W.R.; Schultz, D.J.; Hanks, G.E. The effect of palliative radiation therapy on epidural compression due to metastatic malignant melanoma. Cancer, 1991, 67(10), 2472-2476.
16. Lui, P.; Cashin, R.; Machado, M.; Hemels, M.; Corey-Lisle, P.K.; Einarson, T.R. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer. Treat. Rev., 2007, 33(8), 665-680.
17. Hill, G.J.; Krementz, E.T.; Hill, H.Z. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer, 1984, 53(6), 1299-1305.
18. Bhatia, S.; Tykodi, S.S.; Thompson, J.A. Treatment of metastatic melanoma: an overview. Oncology (Williston Park), 2009, 23(6), 488-496.
19. Chapman, P.B.; Einhorn, L.H.; Meyers, M.L.; Saxman, S.; Destro, A.N.; Panageas, K.S.; Begg, C.B.; Agarwala, S.S.; Schuchter, L.M.; Ernstoff, M.S.; Houghton, A.N.; Kirkwood, J.M. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol., 1999, 17(9), 2745-2751.
20. Eton, O.; Legha, S.S.; Bedikian, A.Y.; Lee, J.J.; Buzaid, A.C.; Hodges, C.; Ring, S.E.; Papadopoulos, N.E.; Plager, C.; East, M.J.; Zhan, F.; Benjamin, R.S. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J. Clin. Oncol., 2002, 20(8), 2045-2052.
21. Legha, S.S.; Ring, S.; Papadopoulos, N.; Plager, C.; Chawla, S.; Benjamin, R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer, 1989, 64(10), 2024-2029.
22. Stevens, M.F.; Hickman, J.A.; Langdon, S.P.; Chubb, D.; Vickers, L.; Stone, R.; Baig, G.; Goddard, C.; Gibson, N.W.; Slack, J.A.; et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res., 1987, 47(22), 5846-5852.
23. Middleton, M.R.; Grob, J.J.; Aaronson, N.; Fierlbeck, G.; Tilgen, W.; Seiter, S.; Gore, M.; Aamdal, S.; Cebon, J.; Coates, A.; Dreno, B.; Henz, M.; Schadendorf, D.; Kapp, A.; Weiss, J.; Fraass, U.; Statkevich, P.; Muller, M.; Thatcher, N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 2000, 18(1), 158-166.
24. Middleton, M.R.; Grob, J.J.; Aaronson, N.; Fierlbeck, G.; Tilgen, W.; Seiter, S.; Gore, M.; Aamdal, S.; Cebon, J.; Coates, A.; Dreno, B.; Henz, M.; Schadendorf, D.; Kapp, A.; Weiss, J.; Fraass, U.; Statkevich, P.; Muller, M.; Thatcher, N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Erratum in: J. Clin. Oncol., 2000,18(11): 2351.
25. Atkins, M.B.; Lotze, M.T.; Dutcher, J.P.; Fisher, R.I.; Weiss, G.; Margolin, K.; Abrams, J.; Sznol, M.; Parkinson, D.; Hawkins, M.; Paradise, C.; Kunkel, L.; Rosenberg, S.A. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol., 1999, 17(7), 2105-2116.
26. Atkins, M.B.; Kunkel, L.; Sznol, M.; Rosenberg, S.A. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am., 2000, 6 (Suppl 1), S11-4.
27. Tsao, H.; Atkins, M.B.; Sober, A.J. Management of cutaneous melanoma. N. Engl. J. Med., 2004, 351(10), 998-1012.
28. Bouwhuis, M.G.; Ten Hagen, T.L.; Suciu, S.; Eggermont, A.M. Autoimmunity and treatment outcome in melanoma. Curr. Opin. Oncol., 2011, 23(2), 170-176.
29. Jilaveanu, L.B.; Aziz, S.A.; Kluger, H.M. Chemotherapy and biologic therapies for melanoma: do they work? Clin. Dermatol., 2009, 27(6), 614-625.
30. Dudley, M.E.; Yang, J.C.; Sherry, R.; Hughes, M.S.; Royal, R.; Kammula, U.; Robbins, P.F.; Huang, J.; Citrin, D.E.; Leitman, S.F.; Wunderlich, J. Restifo, N.P.; Thomasian, A.; Downey, S.G.; Smith, F.O.; Klapper, J.; Morton, K.; Laurencot, C.; White, D.E.; Rosenberg, S.A; Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol., 2008, 26(32), 5233-5239.
31. nd; Crum, E.; McKnight, J.E.; Hawkins, M.J.; Jones, M.J.; Longo, D.L.; Urba, W.J. Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res., 1989, 49(7), 1871-1876.
32. Creagan, E.T.; Ahmann, D.L.; Frytak, S.; Long, H.J.; Chang, M.N.; Itri, L.M. Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses. Cancer, 1987, 59(3 Suppl), 638-646.
33. Robinson, W.A.; Mughal, T.I.; Thomas, M.R.; Johnson, M.; Spiegel, R.J. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiology, 1986, 172(3-5), 275-282.
34. Kirkwood, J.M.; Ibrahim, J.G.; Sondak, V.K.; Richards, J.; Flaherty, L.E.; Ernstoff, M.S.; Smith, T.J.; Rao, U.; Steele, M.; Blum, R.H. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol., 2000, 18(12), 2444-2458.
35. Dummer, R.; Garbe, C.; Thompson, J.A.; Eggermont, A.M.; Yoo, K.; Maier, T.; Bergstrom, B. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J. Clin. Oncol., 2006, 24(7), 1188-1194.
36. Hamm, C.; Verma, S.; Petrella, T.; Bak, K.; Charette, M. Melanoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review. Cancer Treat. Rev., 2008, 34(2), 145-156.
37. Legha, S.S.; Ring, S.; Bedikian, A.; Plager, C.; Eton, O.; Buzaid, A.C.; Papadopoulos, N. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann. Oncol., 1996, 7(8), 827-835.
38. Legha, S.S.; Ring, S.; Eton, O.; Bedikian, A.; Plager, C.; Papadopoulos, N. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. Cancer J. Sci. Am., 1997, 3 (Suppl 1), S9-15.
39. Ridolfi, R.; Chiarion-Sileni, V.; Guida, M.; Romanini, A.; Labianca, R.; Freschi, A.; Lo Re, G.; Nortilli, R.; Brugnara, S.; Vitali, P.; Nanni, O. Italian Melanoma Intergroup. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J. Clin. Oncol., 2002, 20(6), 1600-1607.
40. Ives, N.J.; Stowe, R.L.; Lorigan, P.; Wheatley, K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J. Clin. Oncol., 2007, 25(34), 5426-5434.
41. Soengas, M.S.; Lowe, S.W. Apoptosis and melanoma chemoresistance. Oncogene, 2003, 22(20), 3138-3151.
42. Cory, S.; Adams, J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer, 2002, 2(9), 647-656.
43. Hengartner, M.O. The biochemistry of apoptosis. Nature, 2000, 407(6805), 770-776.
44. Helmbach, H.; Rossmann, E.; Kern, M.A.; Schadendorf, D. Drugresistance in human melanoma. Int. J. Cancer, 2001, 93(5), 617-622.
45. Galluzzi, L.; Larochette, N.; Zamzami, N.; Kroemer, G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene, 2006, 25(34), 4812-4830.
46. Bush, J.A.; Li, G. The role of Bcl-2 family members in the progression of cutaneous melanoma. Clin. Exp. Metastasis, 2003, 20(6), 531-539.
47. Zhuang, L.; Lee, C.S.; Scolyer, R.A.; McCarthy, S.W.; Zhang, X.D.; Thompson, J.F.; Hersey, P. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod. Pathol., 2007, 20(4), 416-426.
48. Hersey, P.; Zhang, X.D. Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma. Pigment Cell Melanoma Res., 2008, 21(3), 358-367.
49. Kim, S.H.; Ricci, M.S.; El-Deiry WS. Mcl-1: a gateway to TRAIL sensitization. Cancer Res., 2008, 68(7), 2062-2064.
50. Selzer, E.; Schlagbauer-Wadl, H.; Okamoto, I.; Pehamberger, H.; Pötter, R.; Jansen, B. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res., 1998, 8(3), 197-203.
51. Nishimura, E.K.; Granter, S.R.; Fisher, D.E. Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science, 2005, 307(5710), 720-724.
52. Jansen, B.; Wacheck, V.; Heere-Ress, E.; Schlagbauer-Wadl, H.; Hoeller, C.; Lucas, T.; Hoermann, M.; Hollenstein, U.; Wolff, K.; Pehamberger, H. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet, 2000, 356(9243), 1728-1733.
53. Bedikian, A.Y.; Millward, M.; Pehamberger, H.; Conry, R.; Gore, M.; Trefzer, U.; Pavlick, A.C.; DeConti, R.; Hersh, E.M.; Hersey, P.; Kirkwood, J.M.; Haluska, F.G. Oblimersen Melanoma Study Group. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol., 2006, 24(29), 4738-4745.
54. Hu, Y.; Cherton-Horvat, G.; Dragowska, V.; Baird, S.; Korneluk, R.G.; Durkin, J.P.; Mayer, L.D.; LaCasse, E.C. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin. Cancer Res., 2003, 9(7), 2826-2836.
55. Hocker, T.L.; Singh, M.K.; Tsao, H.; Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J. Invest. Dermatol., 2008, 128(11), 2575-2595.
56. Scaffidi, C.; Fulda, S.; Srinivasan, A.; Friesen, C.; Li, F.; Tomaselli, K.J.; Debatin, K.M.; Krammer, P.H.; Peter, M.E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J., 1998, 17(6), 1675-1687.
57. Zhang, X.D.; Franco, A.; Myers, K.; Gray, C.; Nguyen, T.; Hersey, P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res., 1999, 59(11), 2747-2753.
58. Zhuang, L.; Lee, C.S.; Scolyer, R.A.; McCarthy, S.W.; Zhang, X.D.; Thompson, J.F.; Screaton, G.; Hersey, P. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. Hum. Pathol., 2006, 37(10), 1286-1294.
59. Johnstone, R.W.; Frew, A.J.; Smyth, M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer, 2008, 8(10), 782-798.
60. Castellano, G.; Torrisi, E.; Ligresti, G.; Malaponte, G.; Militello, L.; Russo, A.E.; McCubrey, J.A.; Canevari, S.; Libra, M. The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle, 2009, 8(9), 1367-1372.
61. Zaravinos, A.; Spandidos, D.A. Yin yang 1 expression in human tumors. Cell Cycle, 2010, 9(3), 512-522.
62. Baritaki, S.; Katsman, A.; Chatterjee, D.; Yeung, K.C.; Spandidos, D.A.; Bonavida, B. Regulation of tumor cell sensitivity to TRAILinduced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 upregulation. J. Immunol., 2007, 179(8), 5441-5453.
63. Baritaki, S.; Suzuki, E.; Umezawa, K.; Spandidos, D.A.; Berenson, J.; Daniels, T.R.; Penichet, M.L.; Jazirehi, A.R.; Palladino, M.; Bonavida, B. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J. Immunol., 2008, 180(9), 6199-6210.
64. Baritaki, S.; Huerta-Yepez, S.; Sakai, T.; Spandidos, D.A.; Bonavida, B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol. Cancer Ther., 2007, 6(4), 1387-1399.
65. Huerta-Yepez, S.; Vega, M.; Escoto-Chavez, S.E.; Murdock, B.; Sakai, T.; Baritaki, S.; Bonavida, B. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Nitric Oxide, 2009, 20(1), 39-52.
66. Mijatovic, S.; Maksimovic-Ivanic, D.; Mojic, M.; Malaponte, G.; Libra, M.; Cardile, V.; Miljkovic, D.; Harhaji, L.; Dabideen, D.; Cheng, K.F.; Bevelacqua, Y.; Donia, M.; Garotta, G.; Al-Abed, Y.; Stosic-Grujicic S, Nicoletti F. Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells. Nitric Oxide, 2008, 19(2), 177-183.
67. Mijatovic, S.; Maksimovic-Ivanic, D.; Mojic, M.; Timotijevic, G.; Miljkovic, D.; Mangano, K.; Donia, M.; Cataldo, A.D.; Al-Abed, Y.; Cheng, K.F.; Stosic-Grujicic, S.; Nicoletti, F. Cytotoxic and immune-sensitizing properties of nitric oxide-modified saquinavir in iNOS-positive human melanoma cells. J. Cell Physiol., 2011, 226(7),1803-1812.
68. Shelton, J.G.; Steelman, L.S.; Lee, J.T.; Knapp, S.L.; Blalock, W.L.; Moye, P.W.; Franklin, R.A.; Pohnert, S.C.; Mirza, A.M.; McMahon, M.; McCubrey, J.A. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene, 2003, 22(16),2478-92.
69. Fecher, L.A.; Amaravadi, R.K.; Flaherty, K.T. The MAPK pathway in melanoma. Curr. Opin. Oncol., 2008, 20(2):183-189.
70. McCubrey, J.A.; Steelman, L.S.; Chappell, W.H.; Abrams, S.L.; Wong, E.W.; Chang, F.; Lehmann, B.; Terrian, D.M.; Milella, M.; Tafuri, A.; Stivala, F.; Libra, M.; Basecke, J.; Evangelisti, C.; Martelli, A.M.; Franklin, R.A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta, 2007, 1773(8): 1263-1284.
71. Platz, A.; Egyhazi, S.; Ringborg, U.; Hansson, J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol. Oncol., 2008, 1(4):395-405.
72. Lin, K.; Baritaki, S.; Militello, L.; Malaponte, G.; Bevelacqua, Y.; Bonavida, B. The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-??B/Snail/RKIP/ PTEN Circuit. Genes. Cancer., 2010, 1(5):409-420.
73. Flaherty, K.T.; McArthur, G. BRAF, a Target in Melanoma; Implications for Solid Tumor Drug Development. Cancer., 2010, 116(21):4902-4913.
74. Sharma, A.; Trivedi, N.R.; Zimmerman, M.A.; Tuveson, D.A.; Smith, C.D.; Robertson, G.P. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res., 2005, 65, 2412-2421.
75. Martelli, A.M.; Evangelisti, C.; Chiarini, F.; McCubrey, J.A. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget., 2010, 1(2), 89-103.
76. Sekulić, A.; Hudson, C.C.; Homme, J.L.; Yin, P.; Otterness, D.M.; Karnitz, L.M.; Abraham, R.T. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res., 2000, 60(13):3504-3513.
77. LoPiccolo, J.; Blumenthal, G.M.; Bernstein, W.B.; Dennis, P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat., 2008, 11(1-2),32-50.
78. Ko, J.M.; Fisher, D.E. A new era: melanoma genetics and therapeutics. J. Pathol., 2011, (2):241-250.
79. Fecher, L.A.; Cummings, S.D.; Keefe, M.J.; Alani, R.M. Toward a molecular classification of melanoma. J. Clin. Oncol., 2007, 25, 1606-1620.
80. Comin-Anduix, B.; Sazegar, H.; Chodon, T.; Matsunaga, D.; Jalil, J.; von Euw, E.; Escuin-Ordinas, H.; Balderas, R.; Chmielowski, B.; Gomez-Navarro, J.; Koya, R.C.; Ribas, A. Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One, 2010, 5(9), e12711.
81. Robert, C.; Ghiringhelli, F. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist, 2009, 14(8):848-861. Review
82. Agarwala, S.S. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Melanoma Res., 2010, 20(1):1-10. Review
83. Tarhini, A.A.; Iqbal, F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco. Targets Ther., 2010, 3,15-25.
84. Tawbi, H.; Nimmagadda, N. Targeted therapy in melanoma. Biologics, 2009, 3, 475-484.
85. Joseph, E.W.; Pratilas, C.A.; Poulikakos, P.I.; Tadi, M.; Wang, W.; Taylor, B.S.; Halilovic, E.; Persaud, Y.; Xing, F.; Viale, A.; Tsai, J.; Chapman, P.B; Bollag, G.; Solit, D.B.; Rosen, N. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. USA, 2010, 107(33):14903-14908.
86. Aziz, S.A.; Jilaveanu, L.B.; Zito, C.; Camp, R.L.; Rimm, D.L.; Conrad, P.; Kluger, H.M. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin. Cancer Res., 2010, 16(24):6029-6039.
87. Courtney, K.D.; Corcoran, R.B.; Engelman, J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol., 2010, 28(6),1075-1083.
88. Weber, J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist, 2008, 13 (Suppl. 4), 16-25.
89. Tarhini, A.; Lo, E.; Minor, D.R. Releasing the brake on the immune system: ipilimumab in melanoma and other tumor. Cancer Biother. Radiopharm., 2010, 25(6):601-613.
90. Banerji, U. Heat shock protein 90 as a drug target: some like it hot. Clin. Cancer Res., 2009, 15(1), 9-14.
91. da Rocha Dias, S.; Friedlos, F.; Light, Y.; Springer, C.; Workman, P.; Marais, R. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res., 2005, 65(23), 10686-10691.
92. Banerji, U.; O'Donnell, A.; Scurr, M.; Pacey, S.; Stapleton, S.; Asad, Y.; Simmons, L.; Maloney, A.; Raynaud, F.; Campbell, M.; Walton, M.; Lakhani, S.; Kaye, S.; Workman, P.; Judson, I. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol., 2005, 23(18), 4152-4161.
93. Ji, Z.; Flaherty, K.T.; Tsao, H. Molecular therapeutic approaches to melanoma. Mol. Aspects Med., 2010, 31(2), 194-204.
94. Qin, J.Z.; Xin, H.; Sitailo, L.A.; Denning, M.F.; Nickoloff, B.J. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res., 2006, 66(19), 9636-9645.
95. Qin, J.Z.; Ziffra, J.; Stennett, L.; Bodner, B.; Bonish, B.K.; Chaturvedi, V.; Bennett, F.; Pollock, P.M.; Trent, J.M.; Hendrix, M.J.; Rizzo, P.; Miele, L.; Nickoloff, B.J. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res., 2005, 65(14), 6282-6293.
96. Markovic, S.N.; Geyer, S.M.; Dawkins, F.; Sharfman, W.; Albertini, M.; Maples, W.; Fracasso, P.M.; Fitch, T.; Lorusso, P.; Adjei, A.A.; Erlichman, C. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer, 2005, 103(12), 2584-2589.
97. Fernández, Y.; Verhaegen, M.; Miller, T.P.; Rush, J.L.; Steiner, P.; Opipari, A.W. Jr.; Lowe, S.W.; Soengas, M.S. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res., 2005, 65(14), 6294-6304.